Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1

Abstract excerpt

The structure-based design of small-molecule inhibitors targeting protein-protein interactions (PPIs) remains a huge challenge as the drug must bind typically wide and shallow protein sites. A PPI target of high interest for hematological cancer therapy is myeloid cell leukemia 1 (Mcl-1), a prosurvival guardian protein from the Bcl-2 family. Despite being previously considered undruggable, seven small-molecule...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell death mechanisms and regulation
• Share to Chronic Myeloid Leukemia Treatments
• Share to Protein Kinase Regulation and GTPase Signaling